IL6 and neoplasm: This pathway not only supports tumor growth despite CDK4/6 blockade but also contributes to a more aggressive and therapy-resistant phenotype, underscoring the therapeutic potential of dual inhibition strategies targeting both CDK4/6 and IL-6/STAT3 in TNBC.